Literature DB >> 9146904

Mineralocorticoid (type I) receptors in the olfactory mucosa of the mammal: studies with [3H]aldosterone and the anti-mineralocorticoid spironolactone.

R C Kern1, J D Foster, D Z Pitovski.   

Abstract

High-affinity, specific binding sites to mineralocorticoids, with characteristics of mineralocorticoid (type I) receptors, have been found in the mammalian olfactory mucosa. In the presence of RU 28362, which blocks low-affinity binding of the labeled hormone to glucocorticoid (type II) receptors, Scatchard analysis of the specific [3H]aldosterone binding indicates that aldosterone binds to a single class of high-affinity (type I) sites with a dissociation constant, Kd, of 1.2 x 10(-9) M and a maximum number of binding sites, Bmax, of 63 fmol/mg dry tissue. Time course of association of [3H]aldosterone and its binding sites showed maximal binding by 30 min at 25 degrees C which remained unchanged up to 90 min. Competition studies performed with 1 x 10(-7)-1 x 10(-5) M spironolactone, a competitive mineralocorticoid antagonist, showed a dose-response reduction of [3H]aldosterone binding, implying that in the olfactory mucosa this compound behaves as an aldosterone antagonist. These results demonstrate significant [3H]aldosterone binding to receptors of high affinity and mineralocorticoid specificity and suggest that the olfactory mucosa is a target site for mineralocorticoid action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146904     DOI: 10.1093/chemse/22.2.141

Source DB:  PubMed          Journal:  Chem Senses        ISSN: 0379-864X            Impact factor:   3.160


  2 in total

1.  Role of endothelin receptor type A on catecholamine regulation in the olfactory bulb of DOCA-salt hypertensive rats: Hemodynamic implications.

Authors:  María J Guil; Mercedes I Schöller; Luis R Cassinotti; Vinicia C Biancardi; Soledad Pitra; Liliana G Bianciotti; Javier E Stern; Marcelo S Vatta
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-08-06       Impact factor: 5.187

2.  Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats.

Authors:  M Mikov; N S Boni; H Al-Salami; K Kuhajda; S Kevresan; S Golocorbin-Kon; J P Fawcett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.